Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07800806 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Selective Antegrade Cerebral Perfusion and Perioperative Optic Nerve Sheath Diameter in Ascending Aortic Surgery

Study acronym: SACP-ONSD
StatusNot Yet Recruiting
PhaseNot applicable
Started2026-09-30
View on ClinicalTrials.gov ↗
In ascending aortic surgery the distal anastomosis may be constructed with the aortic cross-clamp maintained, or, where the extent of the aortic pathology and the geometry of the graft require it, after release of the cross-clamp during a period of systemic circulatory arrest. Both are established surgical approaches. Where the cross-clamp is released, selective antegrade cerebral perfusion (SACP) is an established cerebral protection technique and is applied for that purpose. Where release of the cross-clamp is not required, systemic circulatory arrest is avoided and SACP is not applied. Optic nerve sheath diameter (ONSD) measured by ocular ultrasonography is a non-invasive marker of raised intracranial pressure. Cardiopulmonary bypass may increase blood-brain barrier permeability through hypoperfusion, non-pulsatile flow, hemodilution and systemic inflammation, predisposing to cerebral edema. Perioperative increases in ONSD have been reported after open heart surgery and have been associated with postoperative delirium. Data on how SACP influences perioperative ONSD dynamics in ascending aortic surgery, and whether such changes relate to postoperative delirium, are limited.
Trial Details
NCT Number NCT07800806
Lead Sponsor Koşuyolu Kartal Heart Training and Research Hospital
Conditions Aortic Diseases, Cardiac Surgical Procedures, Aortic Aneurysm, Thoracic, Delirium - Postoperative, Postoperative Complications (Cardiopulmonary), Postoperative Complications, Cerebrovascular Circulation
Enrollment 134 participants
Start Date 2026-09-30
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-02